Toggle light / dark theme

2016-01-29-1454078214-8291223-Patterson_cancer.jpg By David Patterson Professor of Computer Science University of California, Berkeley This ancient assassin, first identified by a pharaoh’s physician, has been killing people for more than 4,600 years. As scientists found therapies for other lethal diseases–such as measles, influenza, and heart disease–cancer moved up this deadly list and will soon be #1; 40% of Americans will face cancer during their lifetimes, with half dying from it. Most of us ignore cancer until someone close is diagnosed, but instead society could zero in on this killer by recording massive data to discover better treatments before a loved one is in its crosshairs.

Cancer is unlimited cell growth caused by problems in DNA. Some people are born with precarious DNA, and others acquire it later. When a cell divides, sometimes it miscopies a small amount of its DNA, and these errors can overwhelm a cell’s defenses to cause cancer. Thus, you can get it without exposure to carcinogens. Cigarettes, radiation, asbestos, and so on simply increase the copy error rate. Speaking figuratively, every time a cell reproduces, we roll the dice on cancer, with such mutagens loading the dice to raise cancer’s chances.

Most cancer studies today use partial genomic information and have fewer than 1,000 patients. One wonders whether their conclusions would still hold if they used complete genomes and increased the number of patients by factors of 10–100.

Read more

Wonderful article on Nanotechnology and cancer with NCI’s Dr. Piotr Grodzinski. NCI established NCI’s with NCI’s Dr. Piotr Grodzinski. The article was published by declara.


Learn about Opportunities in Cancer Nanotechnology: A Conversation with NCI’s Dr. Piotr Grodzinski. Declara makes it easy to discover, share and organize knowledge. We empower individuals, organizations and countries to develop the knowledge needed to solve big problems.

Read more

A British teenager has become the first child in the UK to be cured of epilepsy by a robot that drilled deep into his brain.

Billy Whitaker, 15, had suffered daily seizures for seven years until the operation two weeks ago, which medical experts are convinced has cured him.

The procedure used a £350,000 ($503,455) robot, practically the same as those used on car factory production lines, to drill electrodes into Whitaker’s brain.

Read more

Researchers are only steps away from bioprinting tissues and organs to solve a myriad of injuries and illnesses. TechRepublic has the inside story of the new product accelerating the process.

If you want to understand how close the medical community is to a quantum leap forward in 3D bioprinting, then you need to look at the work that one intern is doing this summer at the University of Louisville.

Read more

A cutting edge surgical procedure is set to improve the quality of life of eligible transplant patients, who will receive a state funded hand transplant.

Leeds Teaching Hospitals NHS Trust will be the first hospital in the UK to offer hand transplants. The hospital is set to begin performing operation towards the latter end of this year (2016).

Notably, consultant plastic surgeon Professor Simon Kay states that this will be the first nationally funded hand transplant hospital: “There have been lots of hand transplants around the world but this is the first time a national funding organisation has closely examined the issue, come up with the conclusion that it’s worth pursuing and is now going to fund it nationally in one centre,” he stated in an interview with the Telegraph.

Read more

NEW YORK, Jan. 28, 2016 /PRNewswire/ — This BCC Research report provides an in-depth study of the liquid biopsy diagnostics industry. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.

Use this report to: Analyze the market for liquid biopsy diagnostics in depth. Gain information on liquid biopsy technologies, clinical applications, industry structure, important liquid biopsy funding initiatives, global markets, patent status and companies. Learn about some of the top research initiatives that are contributing to liquid biopsy development. Gain information on various liquid biopsy diagnostics markets, including for reproductive health, cancer and transplant diagnostics

Highlights.

Read more

NGS — news flash; gene editing corrects genetically linked liver disease.


For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected. Delivery of the vector to newborn mice improved their survival while treatment of adult animals, unexpectedly, made them worse, according to a new study by investigators from the Perelman School of Medicine at the University of Pennsylvania The team published their findings in Nature Biotechnology.

“Correcting a disease-causing mutation following birth in this animal model brings us one step closer to realizing the potential of personalized medicine,” said senior author James Wilson, MD, PhD, a professor of Medicine and director of the Orphan Disease Center at Penn. “Nevertheless, my 35-year career in gene therapy has taught me how difficult translating mouse studies to successful human treatments can be. From this study, we are now adjusting the gene-editing system in the next phases of our investigation to address the unforeseen complications seen in adult animals.” Wilson is also director of the Penn Gene Therapy Program.

The Wilson lab focused on liver as a target for gene editing since they had solved the problem of gene delivery in this organ in previous work using traditional gene therapy using vectors based on adeno-associated virus (AAV). However, gene replacement therapy with AAV is not ideal for treating genetic diseases of the liver that manifest as newborns since the non-integrating genome is lost as developing liver cells proliferate.

Read more